that, in practical terms, the test was not suitable in its present form for routine cancer screening. However, the relatively high percentage of positive tests in early cancer indicate the possible role of monitoring the patients' response to treatment, in detecting the recurrence of tumour at an early stage and in differential diagnosis.
Further studies are currently in hand to investigate the possible role of the Makari intradermal test in the monitoring of response to treatment and in the early detection of recurrent tumour. The preliminary results of these studies indicate that the surgical removal of a tumour may lead to the conversion of the Makari skin test from positive to negative and during the follow-up period a negative test may convert to positive on the appearance of local or distant recurrence of the tumour. It is important to stress that these data are of a preliminary nature and that further experience is required with more cases and a considerably longer period of follow-up. Nevertheless, the present data strongly support the need for further studies in relation to the monitoring of treatment and the detection of recurrent tumour.
THE VALUE OF HORMONE MEAS-UREMENTS IN TUMOUR MANAGE-MENT. K. D. BAGSHAWE. Department of Medical Oncology, Charing Cross Hospital, London
The practice of measuring hormones and other substances produced by tumours, or by specific organs in response to tumours, is becoming a major occupation in the cancer field. One of the problems is to match the resources available to the problems which can be defined and the distinction between research and clinical routine operation requires constant assessment. The range of possible measurements is already very wide and the number of patients to whom tests are applicable is already large even though most of the measurements do not yet relate to the commonest malignancies.
The measurement of tumour products as diagnostic aids is well established as a means of distinguishing between neoplastic and nonneoplastic causes for certain rare but " interesting" syndromes. But some important applications are slow to reach clinical practice, possibly because the conditions themselves are not regarded as "interesting" to physicians.
Measurements may be applied to problems of tumour localization. Selective venous sampling probably has a limited area of application but it has a requirement for precision in measurements which is not readily sustained on a routine basis. Localization of tumours within the CNS can take advantage of the blood-brain barrier and although such methods have been available for gonadotrophin producing tumours for the past decade, their use has not been widespread even though they are of substantial practical value.
Screening operations based on tumour products are valid for only a limited range of tumours at the present time. Again, the interval between developing a technology appropriate to such a problem and putting it into clinical operation may be very long. In the case of uncommon tumours, screening programmes are practicable only if carried out on a regional or national basis.
The concept of monitoring the clinical course of tumours with serial measurements has been established for a limited range of tumours and it is clear that it may sometimes be necessary to follow more than a single indicator substance. Different indicator substances may provide different forms of information and the form of information provided by a given indicator substance may be different for different tumours. Nevertheless, some propositions currently discussed in this field should perhaps be examined critically. Do we really mean " predictive " tests? Also, where we are threatened by complexity we should perhaps seek to avoid it at the outset and extract a maximum of information from the simplest measurements. " Multiparametric Analysis " is not an end in itself and may be a passing reflection of present inadequacies.
HORMONES AND THE PROSTATE. K. GRIFFITHS. Tenovus Institute for Cancer Research, Welsh National School of Medicine, Cardiff.
Regression of prostatic carcinoma in a large proportion of patients treated by antiandrogen therapy, either castration or oestrogen administration, clearly indicates the
